Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

Shahneen Sandhu, PhD, MBBS, FRACP Enhanced antitumor activity was demonstrated with the addition of the PARP inhibitor olaparib (Lynparza) to the lutetium radioligand Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to early results from the Phase 1 LuPARP study (NCT03874884).1 Among 32 patients treated at various …

Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC Read More »